POEM

A PHASE IIA PHARMACOKINETIC-PHARMACODYNAMIC STUDY TO CONFIRM THE INHIBITORY EFFECT OF TEMSIROLIMUS, TARGETING THE MTOR PATHWAY IN ENDOMETRIAL CARCINOMA

TYPE OF APPLICATION: CLINICAL TRIAL OF NEW INDICATION.

EXPERIMENTAL DRUG: THE STUDY DOSE OF TEMSIROLIMUS WILL BE 25 MG ADMINISTERED INTRAVENOUSLY, INFUSED OVER A 30- TO 60-MINUTE PERIOD ONCE WEEKLY FOR 28 DAYS (TOTAL DOSES: 4 DOSES). TEMSIROLIMUS IS A SELECTIVE INHIBITOR OF MTOR (MAMMALIAN TARGET OF RAPAMYCIN). PHARMACOTHERAPEUTIC GROUP: PROTEIN KINASE INHIBITORS; ATC CODE: L01X E09.

​

​

POEM AT CLINICALTRIALS.GOV